GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ananda Pharma PLC (AQSE:ANA) » Definitions » Minority Interest

Ananda Pharma (AQSE:ANA) Minority Interest : £0.00 Mil (As of Jul. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ananda Pharma Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Ananda Pharma's minority interest for the quarter that ended in Jul. 2024 was £0.00 Mil.


Ananda Pharma Minority Interest Historical Data

The historical data trend for Ananda Pharma's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ananda Pharma Minority Interest Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23
Minority Interest
- - - - -

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jul24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ananda Pharma Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Ananda Pharma Business Description

Traded in Other Exchanges
N/A
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is focused on the development of cannabinoid therapies for the treatment of a range of complex conditions. The company is developing NHS-approved and MHRA-licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure.

Ananda Pharma Headlines

No Headlines